Increased spending in medical research are expected to boost the growth of the global stem cell therapy market at a CAGR of 10.74% during the forecast periodof 2020 to 2027

Market Research Future (MRFR) has published a cooked research report onthe “Global Stem Cell Therapy Market” that contains the information from 2017 to 2027.

The stem cell therapy market is expected to register a CAGR of 10.74% during the forecast period.

MRFR recognizes the following companies as the key players in the global stem cell therapy market—Seraxis, Inc. (Germany), ViaCyte, Inc. (US), Betalin Therapeutics Ltd (Israel), NextCell Pharma AB (US), Kadimastem (Israel), Vertex Pharmaceuticals (US), Fresenius Medical Care AG & Co. KGaA (Germany), Sernava Corp (Canada), Novo Nordisk A/S (Denmark),and Generex Biotechnology (Canada).

Market Highlights

The global stem cell therapy market is expected to register a CAGR of 10.74% during the forecast period and hit USD 11,607.49 millionby 2027.

Stem cell therapy includes the use of stem cells to treat or prevent a disease or condition. The main factors expected to drive the market growth are the increasing prevalence of chronic disorders, the growing pharmaceutical industry, and increasing spending on medical research.

The growth of the global stem cell therapy market is attributed to the growing prevalence of chronic diseases and the growing pharmaceutical industry with increased spending on medical research. Furthermore, an increase in the number of clinical studies for stem cell therapy is, driving the market growth. However, the ethical concerns related to embryonic stem cell-based therapies and the associated high costs may hamper the market growth.

Segment Analysis

The global stem cell therapy market has been divided based on cell source, type, application, and end user.The market, based on cell source, has been segregated into adipose tissue, bone marrow, Embryo/Cord Blood-Derived, Neural, IPSCs, and PPSCs.

The market, based on type, is segmented into allogenic and autologous.The global stem cell therapy market, on the basis of application, is segmented into diabetes, musculoskeletal disorders, cancer, cardiovascular disorders, gastrointestinal diseases, and others.The global stem cell therapy market, on the basis of end user, is segmented into hospitals & clinics, academic research centers, and others.

Access full report @ https://www.marketresearchfuture.com/reports/stem-cell-therapy-market-6422

Regional Analysis

The global stem cell therapy market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to dominate with the largest market share due to increased public-private financing and research grants for producing safe and effective stem cell therapy products. The presence of key players in the region is the primaryfactor driving America’s stem cell therapy market. For instance, in April 2018, Sangamo Therapeutics, Inc., US, received a USD 8 million grant from the California Institute for Regenerative Medicine (CIRM) to evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia.

Europe holds the second-largest market share due to the increased willingness of patients to undergo stem cell treatment and a growing number of cases of chronic and neurological disorders. For instance, according to GLOBOCAN’s Global Cancer Statistics 2020, there were an estimated 19.3 million new cancer cases and around 10 million cancer deaths.

Asia-Pacific is the fastest-growing regional market for stem cell therapies as it is developing rapidly and has witnessed the emergence of many players. Moreover, the rising prevalence of cancer, and growing adoption of stem cell therapy treatments in the region, are likely to drive the market’s growth. According to GLOBOCAN’s Global Cancer Statistics 2020, out of the estimated 19.3 million new cancer cases worldwide, Asia held the largest share of cases with the prevalence of around 50% of total cancer cases and 58.3% of total cancer deaths in 2020.

Key Findings of the Study

• The global stem cell therapy market was valued at USD 5,735.12millionin 2020 and is projected to register a CAGR of10.74% during the assessment period.


• The Americas accounted for the largest share of the global market due to the well-developed healthcare sector, rising prevalence and incidence rate of chronic diseases, and the presence of leading players.


• Based on cell source, the adipose tissuesegment accounted for the largest market share of 35.29% in 2020.


• On the basis oftype of test, the allogenic segment is expected to register the highesr CAGR of 77.22% during the forecast period.


• By application, the diabetessegment accounted for the largest market share of 27.33%in 2020.


• Based on end user, the hospitals & clinics segment accounted for the largest market share of 46.57% in 2020.


• Seraxis, Inc. (Germany), ViaCyte, Inc. (US), Betalin Therapeutics Ltd (Israel), and NextCell Pharma AB (US) are the key market players.